Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo

Neural Regeneration Research

Volumn 8, Issue 22, 2013, Pages 2093-2102

  Fan, Cun Gang ^a   Wang, Dong Liang ^a   Zhang, Qing Jun ^a   Zhou, Jing Ru ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Cell based therapy; Glioma; Grants supported paper; Mesenchymal stem cell; Migration; Neural regeneration; Neuroregeneration; Umbilical cord

Indexed keywords

BETA1 INTEGRIN; CELL THERAPY AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; HERMES ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; THY 1 ANTIGEN;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELL; NERVE CELL; NONHUMAN; NORMAL HUMAN; RAT; UMBILICAL CORD; ADULT; ANIMAL CELL; CELL CULTURE; IN VITRO STUDY; STEM CELL TRANSPLANTATION; TROPISM; TUMOR MICROENVIRONMENT; UMBILICAL CORD MESENCHYMAL STEM CELL;

EID: 84886692414     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.22.009     Document Type: Article

References (53)

1. CBTRUS. CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2011. Available at: www.cbtrus.org.
2. CBTRUS. 2009-2010 CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in United States in 2002-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2009-2010. Available at: www.cbtrus.org.
3. Baehring JM. Glioblastoma multiforme-new approaches to therapy. Cancer J. 2012;18(1):11.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
5. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49 (3):333-343.
6. Fan CG, Zhang QJ. Interpretation of "High-grade malignant glioma - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Guoji Shenjing Bingxue Shenjing Waikexue Zazhi. 2012;39(6):570-573.
7. Lamborn KR, Yung WK, Chang SM, et al. Progression- free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
8. Fan CG, Zhang QJ. Interpretation of "Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme". Zhongguo Linchuang Shenjing Waike Zazhi. in press.
9. McNamara MG, Mason WP. Antiangiogenic therapies in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012;12(5):643-654.
10. Buie LW, Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother. 2008;42(10):1486-1490.
11. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11): 1131-1138.
12. Specenier P. Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012;12(1):9-18.
13. Armstrong TS, Wen PY, Gilbert MR, et al. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012;14(10): 1203-1214.
14. Gerstner ER, Batchelor TT. Antiangiogenic therapy for glioblastoma. Cancer J. 2012;18(1):45-50.
15. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
16. Thomas AA, Ernstoff MS, Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J. 2012;18(1):59-68.
17. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 2012;18(1):69-81.
18. Mohyeldin A, Chiocca EA. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J. 2012;18(1):82-88.
19. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2007;79(3-4):141-152.
20. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009; 9(10):1519-1527.
21. Muller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci. 2006;7(1):75-84.
22. Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol. 2006;8(2):119-126.
23. Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol. 2012;14(3):256-265.
24. Kosztowski T, Zaidi HA, Quiñones-Hinojosa A. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther. 2009;9(5): 597-612.
25. Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011;7(1):130-140.
26. Bexell D, Scheding S, Bengzon J. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther. 2010;18(6):1067-1075.
27. Fan CG, Zhang QJ. Tropism of bone marrow mesenchymal stem cells for glioma. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(36):6815-6819.
28. Fan CG, Zhang QJ. Application prospect of bone marrow mesenchymal stem cells in the treatment of glioma. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(41):7737-7741.
29. Fan CG, Zhou JR, Zhang QJ. Therapeutic potential of huam umbilical cord blood derived mesenchymal stem cells in therapy of glioma. Guo Ji Shen Jing Bing Xue Shen Jing Wai Ke Xue Za Zhi. 2011;38(6):604-607.
30. Wang GS, Zhang QJ, Han ZC. Evaluation of neurological function recovery following human umbilical cord mesenchymal stem cells transplantation to injured spinal cord in rats. Zhonghua Shenjing Waike Zazhi. 2006;22(10):18-21.
31. Fan CG, Tang FW, Zhang QJ, et al. Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell transplant. 2005;14(5):311-321.
32. Fan CG, Zhang QJ, Han ZC. Neural differentiation of mesenchymal stem cells from umbilical cord. Zhonghua Shenjing Waike Zazhi. 2005;21(7):388-392.
33. Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
34. Koh SH, Kim KS, Choi MR, et al. Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res. 2008;1229:233-248.
35. Liao W, Zhong J, Yu J, et al. Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis. Cell Physiol Biochem. 2009;24 (3-4):307-316.
36. Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells. 2006;24(3):781-792.
37. Zhang S, Liu XZ, Liu ZL, et al. Stem cells modified by brain-derived neurotrophic factor to promote stem cells differentiation into neurons and enhance neuromotor function after brain injury. Chin J Traumatol. 2009;12(4): 195-199.
38. Fan CG, Zhang QJ. The potentials of human adipose tissue derived mesenchymal stem cells in targeted therapy of experimental glioma. Zhongguo Xiandai Shenjing Jibing Zazhi. 2012;12(6):651-654.
39. Fan CG, Zhang QJ, Zhou JR. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev. 2011;7(1):195-207.
40. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res. 2008;314(9):1937-1944.
41. Shetty P, Cooper K, Viswanathan C. Comparison of proliferative and multilineage differentiation potentials of cord matrix, cord blood, and bone marrow mesenchymal stem cells. Asian J Transfus Sci. 2010;4(1):14-24.
42. Schichor C, Birnbaum T, Etminan N, et al. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol. 2006;199(2):301-310.
43. Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol. 2007;83(3): 241-247.
44. Hata N, Shinojima N, Gumin J, et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010;66(1):144-156.
45. Ho IA, Chan KY, Ng WH, et al. Matrix metalloproteinase 1 is necessary for the migration of human bone marrowderived mesenchymal stem cells toward human glioma. Stem Cells. 2009;27(6):1366-1375.
46. Chien LY, Hsiao JK, Hsu SC, et al. In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model. Biomaterials. 2011;32(12): 3275-3284.
47. Park SA, Ryu CH, Kim SM, et al. CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int J Oncol. 2011;38(1):97-103.
48. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846-1251.
49. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 2007;40(7): 609-619.
50. Panciani PP, Fontanella M, Tamagno I, et al. Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred? J Neurosurg Sci. 2012; 56(3):221-229.
51. Boulland JL, Leung DS, Thuen M, et al. Evaluation of intracellular labeling with micron-sized particles of iron oxide (MPIOs) as a general tool for in vitro and in vivo tracking of human stem and progenitor cells. Cell Transplant. 2012;21(8):1743-1759.
52. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
53. Dai Y, Sun AH, Fan CG, et al. Mesenchymal stem cells (MSCs) show tropsim for intracranial gliomas in adult rats. Zhongguo Shenjing Jiepou Zazhi. 2005;21(1):45-49.